SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

DSMC Monitoring Update for Stanford Cancer Institute IITs

October 11, 2022 - SCI Communications

For studies that require DSMC monitoring and involve administration of investigational products (IP): 

Starting November 1, 2022, signed drug orders for oral IP will be requested as part of the study monitoring. 

Starting January 1, 2023, signed drug orders for any IP, regardless of type (oral, topical, intravenous, radiopharmaceutical, other), will be requested as part of the study monitoring. 

Of note, if your study utilizes Beacon for investigational drug orders, please indicate that in the monitoring questionnaire. In which case, you do not need to provide the drug orders, if you are able to confirm that the drug orders are available in Beacon. 

We ask that all drug orders are provided for the patients selected for monitoring. This change will be reflected in the monitoring requests that are sent out. If you have any questions or concerns, please reach out to our quality monitors at dsmc-quality@stanford.edu

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • PRISM
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube